



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Flupirtine Maleate (Standard)

Cat. No.:	HY-17001R
CAS No.:	75507-68-5
Molecular Formula:	C <sub>19</sub> H <sub>21</sub> FN <sub>4</sub> O <sub>6</sub>
Molecular Weight:	420.39
Target:	Potassium Channel; iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Flupirtine (Maleate) (Standard) is the analytical standard of Flupirtine (Maleate). This product is intended for research and analytical applications. Flupirtine Maleate is a brain penetrant, and orally bioavailable, non-opioid and centrally acting analgesic agent. Flupirtine Maleate is an indirect N-methyl-D-aspartate receptor (NMDAR) antagonist. Neuroprotective properties<sup>[1][2]</sup>.

### REFERENCES

- [1]. Jan Dörr, et al. Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial. *Front Neurol.* 2018 Oct 9;9:842.
- [2]. Hanna M Jaeger, et al. The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angiogenesis. *Oncotarget.* 2015 Jun 10;6(16):14033-44.
- [3]. Elango Panchanathan, Effect of flupirtine on the growth and viability of U373 malignant glioma cells. *Cancer Biol Med.* 2013 Sep;10(3):142-7.
- [4]. Martin J Gunthorpe, et al. The mechanism of action of retigabine (ezogabine), a first-in-class K<sup>+</sup> channel opener for the treatment of epilepsy. *Epilepsia.* 2012 Mar;53(3):412-24.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA